Concordia International photodynamic therapy laser treatment receives FDA approval

Pharmaceutical company Concordia International (Oakville, ON, Canada) has received FDA approval for its Photofrin 630 PDT laser, a light-based cancer treatment that combines a photosensitizing drug called Photofrin (porfimer sodium) with a specific type of light administered by a laser to attack cancer cells.

The newly approved photodynamic therapy (PDT) laser, which is designed for use with Photofrin to treat esophageal cancer, Barrett's esophagus, and non-small cell lung cancer, has been re-engineered with technological advancements in laser design. These advancements include new controls and peripheral systems while maintaining the same specifications with minimal changes to the treatment procedures.

The company is also evaluating Photofrin as a rare disease product candidate through a Phase 3 clinical trial. The ongoing trial is evaluating the product's safety and efficacy as a potential treatment for cholangiocarcinoma (bile duct cancer), which is a rare disease affecting approximately 20003000 patients annually in the United States.

For more information, please visit http://concordiarx.com.